Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/eficiencia-de-las-nuevas-opciones-terap-uticas-para-el-tratamiento-de-MfIPIiQLBX
References (63)
-
K. Johnson, B. Brooks, Jeffrey Cohen, C. Ford, Jill Goldstein, R. Lisak, L. Myers, H. Panitch, J. Rose, R. Schiffer, T. Vollmer, L. Weiner, J. Wolinsky (1995)
Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosisNeurology, 45
-
N. Murphy, C. Confavreux, J. Haas, N. König, E. Roullet, M. Sailer, M. Swash, C. Young, J. Mérot (1998)
Economic Evaluation of Multiple Sclerosis in the UK, Germany and FrancePharmacoEconomics, 13
-
G. Furneri, L. Santoni, Chiara Marchesi, S. Iannazzo, P. Cortesi, P. Piacentini, A. Caputi, L. Mantovani (2015)
Cost-Effectiveness Analysis of Delayed-Release Dimethyl-Fumarate In The Treatment of Relapsing-Remitting Multiple Sclerosis In Italy.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 18 7
-
M. Raikou, M. Kalogeropoulou, G. Rombopoulos (2015)
A Cost-Effectiveness Analysis of Fingolimod Versus Dimethyl Fumarate As A Second-Line Disease Modifying Treatment In Patients With Highly Active Relapsing-Remitting Multiple Sclerosis.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 18 7
-
N. Silva, M. Takemoto, A. Damasceno, Y. Fragoso, A. Finkelsztejn, J. Becker, M. Gonçalves, C. Tilbery, E. Oliveira, D. Callegaro, F. Boulos (2016)
Cost analysis of multiple sclerosis in Brazil: a cross-sectional multicenter studyBMC Health Services Research, 16
-
A. Coles, E. Fox, A. Vladic, S. Gazda, V. Brinar, K. Selmaj, A. Skoromets, I. Stolyarov, Ann Bass, H. Sullivan, D. Margolin, S. Lake, S. Moran, J. Palmer, M. Smith, D. Compston (2012)
Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 Clinical TrialNeurology, 78
-
D. Granfeldt, Å. Björstad, S. Öhrman, I. Björholt (2015)
The Cost Effectiveness of Delayed-Release Dimethyl Fumarate Versus Interferon Beta-1b In A Swedish Setting.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 18 7
-
J. Olsen, A. Wirén (2015)
Cost-Effectiveness of Dimethyl Fumarate Treatment for Relapsing-Remitting Multiple Sclerosis From A Danish Perspective.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 18 7
-
J. Mauskopf, M. Fay, R. Iyer, S. Sarda, T. Livingston (2016)
Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United StatesJournal of Medical Economics, 19
-
F. Henriksson, S. Fredrikson, T. Masterman, B. Jönsson (2001)
Costs, quality of life and disease severity in multiple sclerosis: a cross‐sectional study in SwedenEuropean Journal of Neurology, 8
-
K Noyes, A Bajorska, A Chappel (2011)
Cost-effectiveness of disease-modifying therapy for multiple sclerosis: a population-based studyNeurology, 77
-
LD Jacobs, DL Cookfair, RA Rudick (1996)
Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)Ann Neurol, 39
-
X Zhang, JW Hay, X Niu (2015)
Cost effectiveness of fingolimod, teriflunomide, dimethyl fumarate and intramuscular interferon- β $\upbeta $ 1a in relapsing-remitting multiple sclerosisCNS Drugs, 29
-
L. Kappos, E. Radue, P. O'Connor, C. Polman, R. Hohlfeld, P. Calabresi, K. Selmaj, C. Agoropoulou, M. Leyk, Lixin Zhang-Auberson, P. Burtin (2010)
A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.The New England journal of medicine, 362 5
-
R. Fox, David Miller, J. Phillips, M. Hutchinson, E. Havrdová, M. Kita, Minhua Yang, K. Raghupathi, M. Novas, M. Sweetser, V. Viglietta, K. Dawson, C. Sindic (2012)
Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.The New England journal of medicine, 367 12
-
D. Paty, D. Li (1993)
Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosisNeurology, 43
-
G. Ebers (1998)
Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosisThe Lancet, 352
-
K. Tolley, M. Hutchinson, X. You, Ping Wang, B. Sperling, A. Taneja, M. Siddiqui, E. Kinter (2015)
A Network Meta-Analysis of Efficacy and Evaluation of Safety of Subcutaneous Pegylated Interferon Beta-1a versus Other Injectable Therapies for the Treatment of Relapsing-Remitting Multiple SclerosisPLoS ONE, 10
-
D. Goodin, A. Reder, G. Ebers, Gary Cutter, M. Kremenchutzky, J. Oger, D. Langdon, M. Rametta, K. Beckmann, T. DeSimone, V. Knappertz (2012)
Survival in MSNeurology, 78
-
S Iannazzo, L Santoni, C Saleri (2015)
Cost-effectiveness analysis of peginterferon beta-1a in italian relapsing remitting multiple sclerosis managementValue Health, 18
-
S Iannazzo, L Santoni, C Saleri (2015)
Budget impact analysis for peginterferon beta-1a in relapsing remitting multiple sclerosis in ItalyValue Health, 18
-
M. Maruszczak, S. Montgomery, M. Griffiths, N. Bergvall, N. Adlard (2015)
Cost-utility of fingolimod compared with dimethyl fumarate in highly active relapsing-remitting multiple sclerosis (RRMS) in EnglandJournal of Medical Economics, 18
-
KP Johnson, BR Brooks, JA Cohen (1995)
Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study GroupNeurology, 45
-
AJ Coles, E Fox, A Vladic (2012)
Alemtuzumab more effective than interferon β $\upbeta $ -1a at 5-year follow-up of CAMMS223 clinical trialNeurology, 78
-
GC Ebers (1998)
Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study GroupLancet, 352
-
Xinke Zhang, J. Hay, X. Niu (2014)
Cost Effectiveness of Fingolimod, Teriflunomide, Dimethyl Fumarate and Intramuscular Interferon-β1a in Relapsing-Remitting Multiple SclerosisCNS Drugs, 29
-
Daniel Hartung, D. Bourdette, Sharia Ahmed, R. Whitham (2015)
The cost of multiple sclerosis drugs in the US and the pharmaceutical industryNeurology, 84
-
C. Dembek, L. White, J. Quach, Andrea Szkurhan, N. Rashid, M. Blasco (2014)
Cost-effectiveness of injectable disease-modifying therapies for the treatment of relapsing forms of multiple sclerosis in SpainThe European Journal of Health Economics, 15
-
P. Calabresi, B. Kieseier, D. Arnold, L. Balcer, A. Boyko, J. Pelletier, Shifang Liu, Ying Zhu, A. Seddighzadeh, S. Hung, A. Deykin (2014)
Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind studyThe Lancet Neurology, 13
-
L. Jacobs, D. Cookfair, R. Rudick, R. Herndon, J. Richert, A. Salazar, J. Fischer, D. Goodkin, C. Granger, J. Simon, J. Alam, D. Bartoszak, D. Bourdette, J. Braiman, C. Brownscheidle, M. Coats, S. Cohan, D. Dougherty, R. Kinkel, M. Mass, F. Munschauer, R. Priore, P. Pullicino, B. Scherokman, B. Weinstock-Guttman, R. Whitham (1996)
Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosisAnnals of Neurology, 39
-
C. Confavreux, P. O'Connor, G. Comi, M. Freedman, Aaron Miller, T. Olsson, J. Wolinsky, T. Bagulho, Jean-Luc Delhay, D. Dukovic, P. Truffinet, L. Kappos (2014)
Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet Neurology, 13
-
Aaron Miller, J. Wolinsky, L. Kappos, G. Comi, M. Freedman, T. Olsson, D. Bauer, M. Bénamor, P. Truffinet, P. O'Connor (2014)
Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet Neurology, 13
-
J Soto Álvarez (2012)
Evaluación económica de medicamentos y tecnologías sanitarias: principios, métodos y aplicaciones en política sanitaria -
J. Bastida, J. Oliva, F. Antoñanzas, A. Garcia-altes, Ramón Gisbert, J. Mar, J. Puig-Junoy (2010)
Propuesta de guía para la evaluación económica aplicada a las tecnologías sanitariasGaceta Sanitaria, 24
-
Shehzad Ali, N. Paracha, S. Cook, G. Giovannoni, G. Comi, K. Rammohan, P. Rieckmann, P. Sørensen, P. Vermersch, S. Greenberg, D. Scott, A. Joyeux (2012)
Reduction in Healthcare and Societal Resource Utilization Associated with Cladribine Tablets in Patients with Relapsing-Remitting Multiple SclerosisClinical Drug Investigation, 32
-
G Comi, M Filippi, JS Wolinsky (2001)
European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging–measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study GroupAnn Neurol, 49
-
Katia Noyes, Alina Bajorska, Andre Chappel, S. Schwid, L. Mehta, Bianca Weinstock-Guttman, Robert Holloway, Andrew Dick (2011)
Cost-effectiveness of disease-modifying therapy for multiple sclerosisNeurology, 77
-
L. Miguel, J. Sá, B. Pinheiro, C. Acosta (2015)
Cost-Utility Analysis of Delayed-Release Dimethyl Fumerate For The Treatment of Relapsing-Remitting Multiple Sclerosis In Portugal.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 18 7
-
E. Dorman, A. Kansal, S. Sarda (2015)
The budget impact of introducing delayed-release dimethyl fumarate for treatment of relapse-remitting multiple sclerosis in CanadaJournal of Medical Economics, 18
-
G. Comi, M. Filippi, J. Wolinsky (2001)
European/Canadian multicenter, double‐blind, randomized, placebo‐controlled study of the effects of glatiramer acetate on magnetic resonance imaging–measured disease activity and burden in patients with relapsing multiple sclerosisAnnals of Neurology, 49
-
L Hernandez, S Guo, H Toro-Diaz (2015)
Cost-effectiveness analysis of peginterferon beta-1a in the treatment of relapsing-remitting multiple sclerosis in IrelandValue Health, 18
-
J. Mauskopf, M. Fay, R. Iyer, T. Livingston (2014)
Cost-Effectiveness Of Delayed-Release Dimethyl Fumarate Compared To Glatiramer Acetate And Fingolimod For The Treatment Of Relapsing-Remitting Multiple SclerosisValue in Health, 17
-
D. Gasche, G. Restovic, V. Casado, P. Ramírez-Boix, J. Lopez (2015)
Cost-Effectiveness Analysis of Delayed-Release Dimethyl Fumarate for The Treatment of Relapsing Remitting Multiple Sclerosis In Spain.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 18 7
-
Mellen Center, J. Cohen, Md, Canada, L. Arnold, E. Fox, Jeff Rey, A. Cohen, A. Coles, Douglas Arnold, C. Confavreux, E. Fox, H. Hartung, E. Havrdová, Krzysztof Selmaj, Howard Weiner, E. Fisher, Vesna Brinar, G. Giovannoni, M. Stojanovic, Bella Ertik, S. Lake, D. Margolin (2012)
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trialThe Lancet, 380
-
PA Calabresi, BC Kieseier, DL Arnold (2014)
Pegylated interferon β $\upbeta $ -1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind studyLancet Neurol, 13
-
P. Vermersch, A. Członkowska, L. Grimaldi, C. Confavreux, G. Comi, L. Kappos, T. Olsson, M. Bénamor, D. Bauer, P. Truffinet, M. Church, Aaron Miller, J. Wolinsky, M. Freedman, P. O'Connor (2014)
Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trialMultiple Sclerosis Journal, 20
-
P. O'Connor, David Li, M. Freedman, A. Bar-Or, G. Rice, C. Confavreux, D. Paty, J. Stewart, R. Scheyer (2006)
A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapsesNeurology, 66
-
J. Kusel, M. Maruszczak, N. Adlard (2015)
Cost-Utility of Fingolimod Compared With Dimethyl Fumarate (Dmf) In Highly Active Relapsing Remitting Multiple Sclerosis (Rrms) In England: Comparison of A Markov and Discrete Event Simulation Model.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 18 7
-
L. Hernandez, Shien Guo, E. Kinter, M. Fay (2016)
Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United StatesJournal of Medical Economics, 19
-
C. Polman, P. O'connor, E. Havrdová, M. Hutchinson, L. Kappos, David Miller, J. Phillips, F. Lublin, G. Giovannoni, A. Wajgt, M. Toal, F. Lynn, M. Panzara, A. Sandrock (2006)
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.The New England journal of medicine, 354 9
-
W Su, A Kansal, C Vicente (2016)
The cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis in CanadaJ Med Econ, 15
-
DM Hartung, DN Bourdette, SM Ahmed (2015)
The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: too big to fail?Neurology, 84
-
J. Álvarez (2012)
Evaluación económica de medicamentos y tecnologías sanitarias -
DS Goodin, AT Reder, GC Ebers (2012)
Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFN β $\upbeta $ -1b trialNeurology, 78
-
G. Giovannoni, G. Comi, S. Cook, K. Rammohan, P. Rieckmann, P. Sørensen, P. Vermersch, P. Chang, A. Hamlett, B. Musch, S. Greenberg (2010)
A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.The New England journal of medicine, 362 5
-
R. Gold, L. Kappos, D. Arnold, A. Bar-Or, G. Giovannoni, K. Selmaj, C. Tornatore, M. Sweetser, Minhua Yang, S. Sheikh, K. Dawson (2012)
Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.The New England journal of medicine, 367 12
-
S Ali, N Paracha, S Cook (2012)
Reduction in healthcare and societal resource utilization associated with cladribine tablets in patients with relapsing-remitting multiple sclerosis: analysis of economic data from the CLARITY StudyDrug Investig, 32
-
Ashley Newton, Christina Stica (2011)
A comprehensive cost-effectiveness analysis of treatments for multiple sclerosis.International journal of MS care, 13 3
-
M Trapero-Bertran (2015)
Integrando la eficiencia en la esclerosis múltiple -
J. Chevalier, C. Chamoux, F. Hammès, A. Chicoye (2016)
Cost-Effectiveness of Treatments for Relapsing Remitting Multiple Sclerosis: A French Societal PerspectivePLoS ONE, 11
-
P. O'Connor, J. Wolinsky, C. Confavreux, G. Comi, L. Kappos, T. Olsson, H. Benzerdjeb, P. Truffinet, Lin Wang, Aaron Miller, M. Freedman (2011)
Randomized trial of oral teriflunomide for relapsing multiple sclerosis.The New England journal of medicine, 365 14
-
T. Saida, S. Kikuchi, Y. Itoyama, Q. Hao, Takayoshi Kurosawa, Kazuo Nagato, D. Tang, Zhang-Auberson Lixin, Jun-ichi Kira (2012)
A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosisMultiple Sclerosis Journal, 18
-
A. Coles, C. Twyman, D. Arnold, Jeffrey Cohen, C. Confavreux, E. Fox, H. Hartung, E. Havrdová, K. Selmaj, H. Weiner, T. Miller, E. Fisher, R. Sandbrink, R. Sandbrink, S. Lake, D. Margolin, P. Oyuela, M. Panzara, D. Compston (2012)
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trialThe Lancet, 380
- Publisher
- Springer Journals
- Copyright
- Copyright © 2018 by Springer Nature Switzerland AG
- Subject
- Pharmacy; Pharmacy
- ISSN
- 1695-405X
- eISSN
- 1989-5453
- DOI
- 10.1007/s40277-018-0081-x
- Publisher site
- See Article on Publisher Site
Abstract
En los dos últimos años hemos asistido en España a la introducción de 4 nuevos medicamentos para el tratamiento de la esclerosis múltiple recurrente remitente. Teriflunomida (Aubagio®, Genzyme, S.L.U.), alemtuzumab (Lemtrada®, Genzyme, S.L.U.), dimetilfumarato (Tecfidera®, Biogen Spain, S.L.) y peginterferón β $\upbeta $ -1a (Plegridy®, Biogen Spain, S.L.) han demostrado su eficacia y seguridad en los ensayos clínicos, recibiendo así recomendación para su comercialización por la Agencia Europea del Medicamento. Más recientemente, dos nuevos productos, cladribina (Mavenclad®, Merck S.L.U.) y ocrelizumab (Ocrevus®, Hoffmann-La Roche) han sido aprobados para el tratamiento de la esclerosis múltiple. Esta revisión pretende recoger los estudios farmacoeconómicos publicados hasta el momento que permitan justificar el uso de dichos fármacos no solo desde un punto de vista puramente clínico, aspecto principal para su elección, sino también desde una vertiente de eficiencia. En el actual entorno económico desfavorable, defender las decisiones terapéuticas utilizando también datos farmacoeconómicos puede ser útil para facilitar el acceso de los pacientes que clínicamente lo requieran a las nuevas opciones terapéuticas.
Journal
PharmacoEconomics Spanish Research Articles – Springer Journals
Published: Jul 20, 2018